Focus should remain on primary vaccines and boosters for populations not protected from severe outcomes with initial vaccination, CDC advisors say, potentially contradicting Biden administration plans for widespread allowance of third COVID-19 shots. A booster authorization by the White House’s planned 20 September timeline would also compromise Pfizer’s ability to finish a placebo-controlled study evaluating the impact of its booster on clinical outcomes.
The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices appears less eager than the White House to quickly clear COVID-19 boosters for all vaccinated Americans, throwing a potential wrench into the Biden administration’s goal of beginning to offer additional shots the week of 20 September.
The White House said on 18 August it plans to offer a third COVID-19 vaccine to people eight months after...